Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings be

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Solventum gains FDA clearance to combine Restrata Matrix with V.A.C. Therapy, potentially expanding

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MW

Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and D

First-of-its-kind clearance combines two advanced wound care technologies into one path for active h

EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fi

Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combi

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks E

NeurAxis (NASDAQ: NRXS - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both heal

Tandem Diabetes Care (NASDAQ: TNDM - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) a

Solventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x a

Tidal Investments LLC trimmed its position in Solventum Corporation (NYSE: SOLV) by 25.0% in the und

SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus

Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Solventum (SOLV) reported earnings 30 days ago. What's next for the stock?

EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management w

UBS analyst Kevin Caliendo maintains Solventum (NYSE:SOLV) with a Buy and raises the price target

Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:SOLV) with a Overweight and raises t

Wedbush analyst Michael Piccolo maintains Solventum (NYSE:SOLV) with a Outperform and raises the

Keybanc analyst Brett Fishbin maintains Solventum (NYSE:SOLV) with a Overweight and raises the pr

Stifel analyst Rick Wise maintains Solventum (NYSE:SOLV) with a Buy and raises the price target f

BTIG analyst Ryan Zimmerman maintains Solventum (NYSE:SOLV) with a Buy and raises the price targe

Solventum (NYSE: SOLV) today announced its intention to pursue a separation of its Health Informatio

Solventum (NYSE:SOLV) reported quarterly earnings of $2.55 per share which beat the analyst consensu

BMO Capital initiates coverage on Solventum (NYSE:SOLV) with a Market Perform rating and announces

Wedbush analyst Michael Piccolo initiates coverage on Solventum (NYSE:SOLV) with a Outperform rat

UBS analyst Kevin Caliendo maintains Solventum (NYSE:SOLV) with a Neutral and lowers the price ta

Stifel analyst Rick Wise maintains Solventum (NYSE:SOLV) with a Buy and lowers the price target f

Wells Fargo analyst Larry Biegelsen maintains Solventum (NYSE:SOLV) with a Equal-Weight and lower

Keybanc analyst Brett Fishbin maintains Solventum (NYSE:SOLV) with a Overweight and raises the pr

Full-Year 2026 GuidanceSolventum is affirming its full year 2026 guidance:Organic sales growth of +2

Solventum (NYSE:SOLV) reported quarterly earnings of $1.48 per share which beat the analyst consensu

Solventum shares are rebounding Thursday after activist investor Trian Fund criticized post‑spin per

Trian believes Solventum would be a considerably more valuable company today if the Board and manage

Keybanc analyst Brett Fishbin maintains Solventum (NYSE:SOLV) with a Overweight and lowers the pr

Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:SOLV) with a Overweight and lowers t

Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrade

Rothschild & Co analyst Jackson Philips initiates coverage on Solventum (NYSE:SOLV) with a Se

Wells Fargo analyst Vik Chopra maintains Solventum (NYSE:SOLV) with a Equal-Weight and lowers the

Keybanc analyst Brett Fishbin maintains Solventum (NYSE:SOLV) with a Overweight and raises the pr

Solventum (NYSE:SOLV) reported quarterly earnings of $1.57 per share which beat the analyst consensu